Skip to Main Content
Bora Pharmaceuticals Completes the Acquisition of Upsher-Smith

Upsher-Smith Divests Two ANDA Products in Exclusive Agreement with New York-Based Pharmaceutical Company

Maple Grove, MN – August 19, 2022 — Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has divested two inactive ANDAs in an exclusive agreement with a New York-based pharmaceutical company. According to the terms of the agreement, the company will update the regulatory filing with the U.S. Food and Drug Administration prior to manufacturing the products. Upsher-Smith will retain the first right to commercialization under a profit share arrangement. Financial terms related to the deal have not been disclosed.

“Upsher-Smith’s focus remains on driving value from on-market products and optimizing its ANDA portfolio through strategic partnerships,” said Rich Fisher, President and COO, Upsher-Smith. “This agreement allows us to progress two dormant assets and contribute to the Company’s near-term profit.”

About Upsher-Smith 

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to consistent product supply. For more information, visit


Join Our Team!

We’re hiring

Search Our Jobs